BRCA1 and metastatic neoplasm: Although treatment with poly-ADP ribose polymerase inhibitors has demonstrated definitive clinical benefit for men with BRCA1/2 + mCRPC [95], it is less clear at this time whether those with OPMC will benefit similarly to those with widely metastatic disease, as further clinical validation will be warranted.